MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA”), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, announces that it has signed a binding letter of intent (LOI) to acquire SKNY Pharmaceuticals, Inc. The transaction includes a $5 million capital infusion-comprised of cash or equivalent consideration-into MIRA, reinforcing its financial position and supporting the advancement of SKNY-1, a preclinical-stage oral drug candidate for weight loss and smoking cessation. Under the terms of the LOI, MIRA will acquire SKNY through a stock exchange, whereby SKNY shareholders will receive shares of MIRA common stock at a valuation determined by an independent third-party firm.
Read the full article: MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals //
Source: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/mira-pharmaceuticals-signs-binding-letter-of-intent-to-acquire-skny-p-1003779